Norwood, Massachusetts – October 31, 2025 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), an oncology and obesity-focused biotechnology company, announced the pricing of a $75 million underwritten public offering, comprising 4.7 million shares of common stock and 1.0 million pre-funded warrants at a price of $13.00 per share. The offering, expected to close by November 3, 2025, will fund ongoing clinical development, working capital, and general corporate purposes, reinforcing Corbus’s strategic focus on innovative cancer and metabolic therapies.
Science Significance
Corbus is advancing a diversified, mechanism-based drug pipeline targeting well-understood biological pathways in oncology and obesity. Its lead assets include CRB-701, a next-generation antibody–drug conjugate (ADC) that targets Nectin-4 to deliver a cytotoxic payload selectively to cancer cells, and CRB-601, an anti-integrin monoclonal antibody blocking TGF-β activation, a key driver of tumor growth and immune suppression. The company also develops CRB-913, a peripherally restricted CB1 inverse agonist for obesity and metabolic diseases. The infusion of capital will accelerate clinical advancement, support early-phase trials, and expand preclinical development for next-generation therapies.
Regulatory Significance
The proceeds from this offering strengthen Corbus’s ability to navigate clinical and regulatory milestones effectively. With several investigational new drug (IND) programs active under FDA oversight, Corbus is focused on advancing assets into later-stage studies with robust safety and efficacy data. The company’s commitment to cGxP standards ensures compliance across manufacturing, preclinical, and clinical operations. The funding will facilitate expanded regulatory submissions, including potential Phase 2 authorizations and Fast Track or Orphan Drug Designation requests for oncology indications.
Business Significance
Advertisement
The $75 million raise reflects strong investor confidence in Corbus’s pipeline and long-term growth prospects. The financing, led by Jefferies LLC as book-running manager, with RBC Capital Markets, LifeSci Capital, and Mizuho Securities USA as lead managers, positions Corbus to maintain financial flexibility amid competitive biotech markets. Proceeds will enhance research continuity, partnership readiness, and pipeline scalability. This transaction underscores the growing investor interest in ADC platforms and metabolic-disease therapeutics, markets projected to expand significantly through 2030.
Patients’ Significance
For patients battling hard-to-treat cancers or obesity-related disorders, Corbus’s expanded funding ensures accelerated access to clinical trials and innovative treatments. The company’s oncology assets are designed to deliver precision therapies that target tumor pathways with minimal off-target toxicity, while its obesity program aims to combat metabolic dysfunction without central-nervous-system side effects. This capital support is therefore directly linked to faster patient-oriented innovation, bringing novel therapeutics closer to market reality.
Policy Significance
The financing aligns with broader health policy trends encouraging innovation in oncology and metabolic diseases. As global regulatory bodies prioritize first-in-class biologics and targeted therapies, capital investments like Corbus’s public offering enable companies to sustain development pipelines that address unmet medical needs. The funding also strengthens the U.S. biotech ecosystem, supporting domestic research, clinical employment, and early-stage innovation frameworks consistent with federal life-science competitiveness goals.
The $75 million public offering marks a pivotal moment for Corbus Pharmaceuticals, equipping it to advance a promising oncology and obesity pipeline through crucial clinical and regulatory stages. By coupling scientific innovation with sound financial strategy, Corbus continues to establish itself as a next-generation Bio-Pharma leader. This capital infusion not only supports immediate development needs but also positions the company for long-term growth, strategic partnerships, and patient-driven outcomes in precision medicine.
Source: Corbus Pharmaceuticals Holdings, Inc. press release
